References
- Lai -C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
- V’kovski P, Kratzel A, and Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Rev Microbiol. 2020;19(3) ;155–170. https://doi.org/https://doi.org/10.1038/s41579-020-00468-6 https://www.nature.com/articles/s41579-020-00468-6?fbclid=IwAR12Xus96HnUxrh6Ih2f8D_jSkG46tXmSuPQMVhVk-kmSxXgPZFIG-skLtU.
- Mallapaty S. Will COVID become a disease of the young? [Online]. Nature; 2021 [ updated July 8; cited 2021 Jul 10]. Available from: https://www.nature.com/articles/d41586-021-01862-7?utm_source=Nature+Briefing&utm_campaign=43a1343c35-briefing-dy-20210708&utm_medium=email&utm_term=0_c9dfd39373-43a1343c35-43387489
- Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Rev Microbiol. 2021;19(7):409–424.
- CDC. SARS-CoV-2 variant classifications and definitions. Electronic. USA: CDC; [ Updated 2021 July 6. Cited 2021 Jul 13], available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
- Zellweger RM, Wartel TA, Marks F, et al. Vaccination against SARS-CoV-2 and disease enhancement–knowns and unknowns. Expert Rev Vaccines. 2020;19(8):691–698.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920–1931.
- Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589.
- Hegarty PK, Sfakianos JP, Giannarini G, et al. COVID-19 and Bacillus Calmette-Guérin: what is the link? Eur Urol Oncol. 2020;3(3):259–261.
- Joy M, Malavika B, and Asirvatham ES, et al. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. Clin Epidemiol Global Health. 2020;9:202–203, . https://doi.org/https://doi.org/10.1016/j.cegh.2020.08.015 https://www.sciencedirect.com/science/article/pii/S2213398420301949
- Amato M, Werba JP, Frigerio B, et al. Relationship between influenza vaccination coverage rate and COVID-19 outbreak: an Italian ecological study. Vaccines (Basel). 2020;8(3):1–11.
- Kumar J, Meena J. Demystifying BCG vaccine and COVID-19 relationship. Indian Pediatr. 2020;57(6):588–589.
- Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020;117(30):17720–17726.
- Antunes AEC, Vinderola G, Xavier-Santos D, et al. Potential contribution of beneficial microbes to face the COVID-19 pandemic. Food Res Int. 2020;136:109577.
- De wals P, and Divangahi M. Could seasonal influenza vaccination influence COVID-19 risk? medRxiv. 2020 2020.2009.2002.20186734
- Wassenaar TM, Buzard GS, Newman DJ. BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data. Lett Appl Microbiol. 2020;71(5):498–505.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
- Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74.
- Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681.
- Haq EU, Yu J, Guo J. Frontiers in the COVID-19 vaccines development. Exp Hematol Oncol. 2020;9(1). https://doi.org/10.1186/s40164-020-00180-4
- WHO, WHO Draft landscape of COVID-19 candidate vaccines . : WHO 2020 25 06 2021 Available from: .
- Pasquale AD, Preiss S, Silva FTD, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015;3(2):320–343.
- Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
- Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–496.
- Smith TR, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):1–13.
- Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–811.
- Seo YB, Suh YS, Ryu JI, et al. Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates. Vaccines (Basel). 2021;9(4):307.
- Manoj S, Babiuk LA, den Hurk S. Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci. 2004;41(1):1–39.
- Liu M. DNA vaccines: a review. J Intern Med. 2003;253(4):402–410.
- Perrie Y, Mohammed AR, Kirby DJ, et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272–280.
- Awate S, Babiuk LAB, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.
- Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608.
- Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–832.
- Sayers S, Ulysse G, Xiang Z, et al. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol. 2012;2012:1–13.
- Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–3762.
- Pulendran B, Arunachalam P S, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475.
- Zhang R, Wang C, Guan Y, et al. Manganese salts function as potent adjuvants. Cell Mol Immunol. 2021;18(5):1222–1234.
- Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr. 2020;32(1):125–138.
- Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005;11(4):S63–S68.
- Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–6389.
- Dey AK, Srivastava IK. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines. 2011;10(2):227–251.
- Wu TYH, Singh M, Miller AT, et al. Rational design of small molecules as vaccine adjuvants. Sci Transl Med. 2014;6(263):263ra160–263ra160.
- Smirnov D, Schmidt JJ, Capecchi JT, et al. Vaccine adjuvant activity of 3m-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine. 2011;29(33):5434–5442.
- Jin P, Li J, Pan H, et al. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):1–6.
- Hodgson SH, Mansatta K, and Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2020;21(2): 26–35. https://doi.org/https://doi.org/10.1016/S1473-3099(20)30773-8 https://www.sciencedirect.com/science/article/pii/S1473309920307738?casa_token=4kfHXtOJALgAAAAA:-4HNx1SbGKPvCc12-azARaRRoBQV1vy3efe9t8wqddReUmc0qvMuk-tlVU2t9xY3RzChfJj1Rypq
- Liang Z, Zhu H, Wang X, et al. Adjuvants for coronavirus vaccines. Front Immunol. 2020;11:2896.
- Grau S, Ferrández O, and Martín-García E, et al. May we overcome the current serious limitations for distributing reconstituted mRNA vaccines? medRxiv. 2021
- Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–186.
- Yang Z, Bogdan P, Nazarian S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci Rep. 2021;11(1):3238.
- Watterson D, Wijesundara DK, Modhiran N, et al. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin Transl Immunol. 2021;10(4).https://doi.org/10.1002/cti2.1269.
- Wang Y, Xie Y, Luo J, et al. Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus. Nano Today. 2021;38:101139.
- Wang Y, Wang L, Cao H, et al. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. J Med Virol. 2021;93(2):892–898.
- Tan HX, Juno JA, Lee WS, et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun. 2021;12(1).https://doi.org/10.1038/s41467-021-21665-8.
- Su QD, Zou YN, Yi Y, et al. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response. Vaccine. 2021;39(8):1241–1247.
- Srivastava V, Niu L, Phadke KS, et al. Induction of potent and durable neutralizing antibodies against SARS-CoV-2 using a receptor binding domain-based immunogen. Front Immunol. 2021;12:637982.
- Rahmani A, Baee M, Saleki K, et al. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. J Biomol Struct Dyn. 2021:1–17. https://doi.org/10.1080/07391102.2021.1876774
- Mandolesi M, Sheward DJ, Hanke L, et al. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Cell Rep Med. 2021;2(4):100252.
- Malladi SK, Singh R, Pandey S, et al. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem. 2021;296.
- Lien CE, Lin YJ, Chen C, et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Sci Rep. 2021;11(1):8761.
- Liang JG, Su D, Song TZ, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12(1). https://doi.org/10.1038/s41467-021-21634-1.
- Jangra S, De Vrieze J, Choi A, et al. Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7/8 agonist-adjuvanted recombinant spike protein vaccine*. Angew Chem Int Ed Engl. 2021;60(17):9467–9473.
- Du Y, Xu Y, Feng J, et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. Vaccine. 2021;39(16): 2280–2287. .
- Chukwudozie OS, Gray CM, Fagbayi TA, et al. Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein. PLoS One. 2021;16(3):e0248061.
- Chauhan V, Rungta T, Rawat M, et al. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach. J Cell Physiol. 2021;236(2):1131–1147.
- Bhardwaj A. In silico multi subunit vaccine design referring spike glycoprotein of SARS-COV-2 (COVID–19): the world pandemic. Indian J Pharm Sci. 2021;83(1):21–31.
- Arunachalam PS, Walls AC, Golden N, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594(7862):253–258. .
- Tahir U, Qamar M, Shahid F, et al. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2. Infect Dis Poverty. 2020;9(1):132.
- Sirohi PR, Gupta J, Somvanshi P, et al. Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein. J Biomol Struct Dyn. 2020:1–12. https://doi.org/10.1080/07391102.2020.1846626
- Singh A, Thakur M, Sharma LK, et al. designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci Rep. 2020;10(1). https://doi.org/10.1038/s41598-020-73371-y.
- Sarkar B, Ullah MA, Johora FT, et al. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2). Immunobiology. 2020;225(3):151955.
- Sarkar B, Ullah MA, Araf Y, et al. engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach. Inf Med Unlocked. 2020;21:100478.
- Safavi A, Kefayat A, Mahdevar E, et al. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine. 2020;38(48):7612–7628.
- Oladipo EK, Ajayi AF, Ariyo OE, et al. Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19. Inf Med Unlocked. 2020;21:100438.
- Ojha R, Gupta N, and Naik B, et al. High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19. Eur J Pharm Sci. 2020;151;105375. https://doi.org/https://doi.org/10.1016/j.ejps.2020.105375 https://www.sciencedirect.com/science/article/abs/pii/S0928098720301640?casa_token=cRWwoL6rQpwAAAAA:JIkqbCxQoRY8dJ13_8i0ruNkiv-Q9c-OfW5MzzFpptfX8yPsqYpeTxtn3T-y3Pg6Db5_ZKHjuP4u.
- Mitra D, Pandey J, and Jain A, et al. In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein. J Biomol Struct Dyn. 2020 Ahead of Preprint 1–14
- Liu X, Drelich A, Li W, et al. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine. 2020;38(46):7205–7212.
- Kumar N, Sood D, Chandra R. Design and optimization of a subunit vaccine targeting COVID-19 molecular shreds using an immunoinformatics framework. RSC Adv. 2020;10(59):35856–35872.
- Kumar A, Kumar P, Saumya KU, et al. Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an in-silico approach. Expert Rev Vaccines. 2020;19(9):887–898.
- Jakhar R, Kaushik S, Gakhar SK. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics. J Med Virol. 2020;92(10):2114–2123.
- Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896.
- Dar HA, Waheed Y, Najmi MH, et al. Multiepitope subunit vaccine design against COVID-19 based on the spike protein of SARS-CoV-2: an in silico analysis. J Immunol Res. 2020;2020:8893483.
- Bhatnager R, Bhasin M, and Arora J, et al. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. J Biomol Struct Dyn. 2020;39(15): 5690–5705. https://doi.org/https://doi.org/10.1080/07391102.2020.1787227
- Bangaru S, Ozorowski G, Turner HL, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370(6520):1089–1094.
- Kumar V, Kancharla S, Kolli P, et al. Reverse vaccinology approach towards the in-silico multiepitope vaccine development against SARS-CoV-2. F1000Res. 2021;10:44.
- Waqas M, Haider A, Rehman A, et al. Immunoinformatics and molecular docking studies predicted potential multiepitope-based peptide vaccine and novel compounds against novel SARS-CoV-2 through virtual screening. Biomed Res Int. 2021;2021:1596834.
- Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372.
- Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–694.
- Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119.
- Peng S, Cao F, Xia Y, et al. Particulate Alum via pickering emulsion for an enhanced COVID-19 vaccine adjuvant. Adv Mater. 2020;32(40):e2004210.
- Qi X, Ke B, Feng Q, et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chem Commun (Camb). 2020;56(61):8683–8686.
- Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24): 2320–2332. .
- Powell AE, Zhang K, Sanyal M, et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent Sci. 2021;7(1):183–199.
- Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–1183.
- Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021:1–9. https://doi.org/10.1080/14760584.2021.1976153.
- Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–2218.
- Liu Z, Xu W, Xia S, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020;5(1). https://doi.org/10.1038/s41392-020-00402-5.
- Steinbuck MP, Seenappa LM, Jakubowski A, et al. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Sci Adv. 2021;7(6). https://doi.org/10.1126/sciadv.abe5819.
- Kalita P, Padhi AK, Zhang KYJ, et al. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020;145:104236.
- Singh H, Jakhar R, Sehrawat N. Designing spike protein (S-protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020;6(11):e05528.
- Behmard E, Soleymani B, Najafi A, et al. Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2. Sci Rep. 2020;10(1):20864.
- Machado LR, Ottolini B. An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses. Front Immunol. 2015;6:115.
- Hoover DM, Chertov O, Lubkowski J. The structure of human β-defensin-1: new insights into structural properties of β-defensins. J Biol Chem. 2001;276(42):39021–39026.
- Ferris LK, Mburu YK, Mathers AR, et al. Human beta-defensin 3 induces maturation of human Langerhans cell–like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol. 2013;133(2):460–468.
- Schutte BC, McCray Jr PB. β-defensins in lung host defense. Annu Rev Physiol. 2002;64(1):709–748.
- Kim J, Yang YL, Jang S-H, et al. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J. 2018;15(1):1–12.
- Wørzner K, Sheward DJ, Schmidt ST, et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine. 2021;63:103197.
- Haun BK, Lai CY, Williams CA, et al. CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 spike S1 immunization. Front Immunol. 2020;11:599587.
- Bonam SR, Partidos CD, Halmuthur SKM, et al. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38(9):771–793.
- Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249–259.
- Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006;25(3–4):135–154.
- Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511.
- Oberemok VV, Laikova KV, Yurchenko KA, et al. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in ‘lasso’ for the multi-faced virus. Inflamm Res. 2020;69(9):801–812.
- Kuo TY, Lin MY, Coffman RL, et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep. 2020;10(1). https://doi.org/10.1038/s41598-020-77077-z.
- Lövgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10(4):401–403.
- Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438.
- Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571.
- Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–1555.
- Laczkó D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724–732.e7.
- Mao L, Chen Z, and Wang Y, et al. Design and application of nanoparticles as vaccine adjuvants against human Corona virus infection. J Inorg Biochem. 2021 219 ;111454 https://doi.org/https://doi.org/10.1016/j.jinorgbio.2021.111454.
- Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother. 2014;10(9):2761–2774.
- Sun Y, Yin Y, and Gong L, et al. Manganese nanodepot augments host immune response against coronavirus. Nano Res. 2020 14 5 ;1260–1272 https://doi.org/https://doi.org/10.1007/s12274-020-3243-5.
- Lei H, Alu A, Yang J, et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):1–3.
- Chen L, Liu B, Sun P, et al. Severe acute respiratory syndrome coronavirus-2 spike protein Nanogel as a pro-antigen strategy with enhanced protective immune responses. Small. 2020;16(46):2004237.
- Hoseini ZS, Hajizade A, Easton AJ, et al. A meta-analysis of the efficiency of metal nanoparticles in vaccine delivery against infectious disease. Nanomedicine. 2021;16(6):481–495.
- Mushegian A, Medzhitov R. Evolutionary perspective on innate immune recognition. J Cell Biol. 2001;155(5):705.
- Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30(6):766–775.
- Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios R. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020;22(4–5):226–229.
- Li Y, Li Y, Cao X, et al. Pattern recognition receptors in zebrafish provide functional and evolutionary insight into innate immune signaling pathways. Cell Mol Immunol. 2017;14(1):80–89.
- Baccala R, Gonzalez-Quintial R, Lawson BR, et al. Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol. 2009;5(8):448.
- Gasteiger G, D’osualdo A, Schubert DA, et al. Cellular innate immunity: an old game with new players. J Innate Immun. 2017;9(2):111–125.
- Brubaker SW, Bonham KS, Zanoni I, et al. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33(1):257–290.
- Tan X, Sun L, Chen J, et al. Detection of microbial infections through innate immune sensing of nucleic acids. Annu Rev Microbiol. 2018;72(1):447–478.
- O’neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors—redefining innate immunity. Nat Rev Immunol. 2013;13(6):453–460.
- Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135–145.
- Patel MC, Shirey KA, Pletneva LM, et al. Novel drugs targeting toll-like receptors for antiviral therapy. Future Virol. 2014;9(9):811–829.
- Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130(6):1071–1082.
- Yokota S-I, Okabayashi T, Fujii N. The battle between virus and host: modulation of toll-like receptor signaling pathways by virus infection. Mediators Inflamm. 2010;2010:1–12.
- Zhang Z, Ohto U, Shimizu T. Toward a structural understanding of nucleic acid‐sensing toll‐like receptors in the innate immune system. FEBS Lett. 2017;591(20):3167–3181.
- Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
- Hennessy EJ, Parker AE, O’neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307.
- Bagchi A, Herrup EA, Warren HS, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007;178(2):1164–1171.
- Matsumiya T, Stafforini DM. Function and regulation of retinoic acid-inducible gene-I. Crit Rev Immunol. 2010;30(6):489–513
- Onomoto K, Onoguchi K, and Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol Immunol. 2021 18 3 ;539–555 https://doi.org/https://doi.org/10.1038/s41423-020-00602-7.
- Liu F, Gu J. Retinoic acid inducible gene-I, more than a virus sensor. Protein Cell. 2011;2(5):351–357.
- Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res. 2011;31(1):27–31.
- Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Genet. 2019;20(11):657–674.
- Xiao TS, Fitzgerald KA. The cGAS-STING pathway for DNA sensing. Mol Cell. 2013;51(2):135–139.
- Zhang X, Bai X-C, Chen ZJ. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity. 2020;53(1):43–53.
- Deb P, Dai J, Singh S, et al. Triggering of the cGAS–STING pathway in human plasmacytoid dendritic cells inhibits TLR9-mediated IFN production. J Immunol. 2020;205(1):223–236.
- Rui Y, Su J, Shen S, et al. Unique and complementary suppression of cGAS-STING and RNA sensing-triggered innate immune responses by SARS-CoV-2 proteins. Signal Transduct Target Ther. 2021;6(1):1–11.
- Neufeldt CJ, Cerikan B, and Cortese M, et al. SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB. bioRxiv. 2020 Preprint https://doi.org/https://doi.org/10.1101/2020.07.21.212639 .
- Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779.
- Gatoo MA, Naseem S, Arfat MY, et al. Physicochemical properties of nanomaterials: implication in associated toxic manifestations. Biomed Res Int. 2014;2014:1–8.